TScan (TCRX) Chief Legal and Strategy Officer granted 350,000 options

Rhea-AI Filing Summary

TScan Therapeutics reported that officer Zoran Zdraveski, Chief Legal and Strategy Officer, received a grant of 350,000 stock options on January 20, 2026. These options give the right to buy TScan voting common stock at an exercise price of $1.12 per share and expire on January 20, 2036.

According to the vesting terms, 25% of the options vest on the one-year anniversary of January 20, 2026, with the remaining options vesting in equal monthly installments over the following 36 months, subject to Mr. Zdraveski’s continued service with the company. After this grant, he beneficially owns 350,000 derivative securities directly in the form of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZDRAVESKI ZORAN

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	01/20/2026		A		350,000		(1)	01/20/2036	Voting Common Stock	350,000	$0.00	350,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney; Chief Legal and Strategy Officer

	/s/ Zoran Zdraveski	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TScan Therapeutics (TCRX) report for Zoran Zdraveski?

TScan Therapeutics reported that Zoran Zdraveski received a grant of 350,000 stock options to buy voting common stock, recorded as an acquisition on January 20, 2026.

What is the exercise price and term of the new TScan (TCRX) stock options?

The stock options granted to Zoran Zdraveski have an exercise price of $1.12 per share and an expiration date of January 20, 2036.

How do the TScan (TCRX) stock options granted to Zoran Zdraveski vest?

25% of the options vest on the one-year anniversary of January 20, 2026, and the remaining options vest in equal monthly installments over the next 36 months, subject to his continued service.

What is Zoran Zdraveski’s role at TScan Therapeutics (TCRX)?

The filing identifies Zoran Zdraveski as an officer of TScan, with the remarks specifying his position as Chief Legal and Strategy Officer.

How many TScan (TCRX) derivative securities does Zoran Zdraveski own after this transaction?

After this grant, 350,000 derivative securities (stock options) are reported as directly beneficially owned by Zoran Zdraveski.

Was this TScan (TCRX) insider transaction a purchase or a grant of options?

The transaction is coded as A (acquired) for a stock option grant, with a per-option price of $0.00, reflecting a compensatory award rather than an open-market purchase.